Effect of Elevated Basal Insulin on Cancer Incidence and Mortality in Cancer Incident Patients: The Israel GOH 29-year follow-up study

Unit of Cardiovascular Epidemiology, The Gertner Institute for Epidemiology and Health Policy Research, Ramat Gan, Israel.
Diabetes care (Impact Factor: 8.42). 05/2012; 35(7):1538-43. DOI: 10.2337/dc11-1513
Source: PubMed


Diabetes is associated with many forms of cancer. Recent evidence has suggested that some treatments for diabetes are associated with an increased cancer risk. Less is known about the association between endogenous insulin in the prediabetes state and cancer risk.
We investigated cumulative cancer incidence and cancer incidence density over 29 years, according to basal insulin, in a cohort of 1,695 nondiabetic men and women of four ethnic origins, aged 51.8 ± 8.0 years at baseline. Total mortality among the 317 subjects (18.7%) who developed cancer at least 2 years after baseline was assessed.
In a Cox proportional hazards model, the all-site hazard ratio of cancer incidence comparing the highest insulin quartile with the other three quartiles was 1.09 (95% CI 0.85-1.40), adjusted for age, sex, and ethnicity. BMI, smoking, and fasting blood glucose were not statistically significant in this model. Basal insulin level was not significantly associated with cancer of specific sites (breast, prostate, colon/rectum, or bladder). Fasting insulin in the upper quartile conferred a 37% increased risk for total mortality among cancer patients, adjusting for age, sex, and ethnic origin (95% CI 0.94-2.00, P = 0.097) compared with that of the lower quartiles. Male sex, older age, and North African origins were associated with a greater risk of mortality during follow-up time.
This long-term cohort study may suggest a role for basal elevated insulin levels, mainly as a negative predictor in cancer prognosis.

Download full-text


Available from: Lital Keinan-Boker, Jun 12, 2014
    • "It has been hypothesised that this leads to increased insulin signalling in epithelial cells that do not become insulin resistant. Retrospective observational cohort studies show increased cancer incidence in patients with T2DM [25] [26] [27] [28] [29]. Detection bias due to increased medical attention in the months after the diagnosis of diabetes appears to explain some, but certainly not all, of this increased incidence [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiological and experimental evidence strongly suggests an association between type 2 diabetes mellitus and cancer. Insulin resistance, causing hyperinsulinaemia and eventually hyperglycaemia, appears to increase cancer incidence and disease progression. In addition, insulin resistance seems to reduce the efficacy of cancer therapy. Treatment with cancer therapeutics such as glucocorticoids, chemotherapy, hormonal therapies and targeted drugs can actually induce insulin resistance. The question arises whether cancer-therapy induced insulin resistance impairs anticancer treatment efficacy and disease outcome. Here, we review current literature regarding the incidence of cancer-therapy induced insulin resistance and describe the systemic and extra- and intracellular changes that occur in insulin signalling pathways and glucose metabolism. Subsequently, clinical and preclinical evidence for consequences of insulin resistance in terms of cancer progression and survival is presented. Finally, potential interventions including diabetes medication and limiting energy availability through diets and exercise are discussed. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Cancer Treatment Reviews 02/2015; 41(4). DOI:10.1016/j.ctrv.2015.02.007 · 7.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes, in particular type 2 diabetes, and cancer are two diseases that appear to be associated. Numerous epidemiological studies indicate indeed that diabetes increases the incidence of several tumors. Chronic hyperglycemia and/or insulin resistance with compensatory hyperinsulinemia could account for the association. On the other hand, the interpretation of the link between diabetes and cancer could be influenced by therapeutical interferences. Considering all these data together, cancer should be considered as a "new potential complication" of diabetes and integrated in the follow-up of diabetic subjects.
    10/2013; 7(4):247-50. DOI:10.1016/j.dsx.2013.08.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: HbA1c testing has become an accepted means of diagnosing diabetes, as an alternative to blood glucose levels. However, population based norms of glucose and of HbA1c levels do not enable the detection of diabetes at an early enough stage to thwart complications. Personal trajectories of glucose levels show steep increases a number of years prior to diabetes diagnosis. Here, we hypothesize that a comparable time-dependent deviation in an individual's HbA1c level may be an early manifestation of disease that should prompt lifestyle modifications. We predict that analysis of personal trajectories of glucose and of HbA1c will promote earlier intervention and a greater reduction in disease complications, than do current standards, which are based on population based norms. Copyright © 2012 John Wiley & Sons, Ltd.
    Diabetes/Metabolism Research and Reviews 01/2013; 29(1). DOI:10.1002/dmrr.2373 · 3.55 Impact Factor
Show more